Skip to Content

Our Team

Uday Khire, Ph.D. MBA, Founder and Chief Executive Officer

Dr. Uday Khire is a synthetic/ medicinal chemist with an exceptional track record. He has over 17 years of experience in medicinal chemistry/ drug discovery. After receiving his Ph.D. from National Chemical Laboratory, India, he carried out post-doctoral studies with Prof. H.C. Brown and Prof. Scott D. Rychnovsky. His Post-doctoral work includes total synthesis of complex polyene macrolide antibiotic, Roflamycoin (JACS 1997, 2058) and developed asymmetric allenyl/ propargylboration of aldehydes. Uday then joined the Bayer Research Center in West Haven, CT in 1997 and since then has worked on numerous preclinical drug discovery projects in the therapeutic areas of diabetes, obesity, and in particular oncology. Uday is a co-inventor of a novel multi-kinase inhibitor, developed jointly by Bayer and Onyx and is approved as first line therapy for kidney and liver cancer in the US and other major markets. Uday has authored numerous peer-reviewed international scientific publications and is an inventor of many patents/patent applications. Uday received his MBA in pharmaceutical management from Fairleigh Dickinson University, New Jersey.

Uday founded Cheminpharma, a chemistry/ medicinal chemistry driven service company in 2007. Under his leadership, Cheminpharma in-licensed “Protein Degradation and Control Technology using Small Molecule Shield-1”. Cheminpharma's in-house research improved water insoluble ligand Shield-1 to a highly water soluble and orally available ligand Aqua-Shield-1 (US20100267950).